Last reviewed 2026-05-19 · How we verify

AZD1152 part A

AstraZeneca · Phase 1 active Small molecule ✓ Verified May 2026 Quality 55/100

AZD1152 part A is a Aurora kinase inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.

Inhibits Aurora B kinase, a protein essential for cell division, leading to mitotic disruption and cancer cell death.

AZD1152 part A is a treatment being studied in a Phase I clinical trial for patients with advanced solid malignancies, including tumors and acute myeloid leukemia. The exact mechanism of AZD1152 part A is unknown.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AZD1152 part A
Sponsor	AstraZeneca
Drug class	Aurora kinase inhibitor
Modality	Small molecule
Phase	Phase 1

Mechanism of action

AZD1152 selectively inhibits Aurora B kinase, which plays a critical role in chromosome segregation and cytokinesis during mitosis. By blocking this enzyme, the drug causes mitotic catastrophe and apoptosis in rapidly dividing cancer cells.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AZD1152 part A CI brief — competitive landscape report
AZD1152 part A updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about AZD1152 part A

What is AZD1152 part A?

AZD1152 part A is a Aurora kinase inhibitor drug developed by AstraZeneca.

How does AZD1152 part A work?

Inhibits Aurora B kinase, a protein essential for cell division, leading to mitotic disruption and cancer cell death.

Who makes AZD1152 part A?

AZD1152 part A is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is AZD1152 part A in?

AZD1152 part A belongs to the Aurora kinase inhibitor class. See all Aurora kinase inhibitor drugs at /class/aurora-kinase-inhibitor.

What development phase is AZD1152 part A in?

AZD1152 part A is in Phase 1.

Drug class: All Aurora kinase inhibitor drugs
Manufacturer: AstraZeneca — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing